AnaptysBio (NASDAQ:ANAB) had its price objective upped by analysts at Royal Bank of Canada to $108.00 in a report issued on Monday, December 18th. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Royal Bank of Canada’s price objective would indicate a potential downside of 3.91% from the company’s previous close.
Other analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of AnaptysBio from a “hold” rating to a “buy” rating and set a $36.00 price objective for the company in a research report on Wednesday, September 13th. Wedbush reaffirmed an “outperform” rating and issued a $75.00 price objective (up previously from $37.00) on shares of AnaptysBio in a research report on Friday, October 13th. Jefferies Group assumed coverage on shares of AnaptysBio in a research report on Thursday, November 9th. They set a “buy” rating and a $101.00 price target for the company. Stifel Nicolaus reissued a “buy” rating and set a $35.00 price target on shares of AnaptysBio in a research report on Tuesday, September 12th. Finally, Robert W. Baird set a $69.00 price target on shares of AnaptysBio and gave the stock a “buy” rating in a research report on Wednesday, October 11th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $88.00.
Shares of AnaptysBio (NASDAQ ANAB) traded up $2.20 during mid-day trading on Monday, hitting $112.40. 285,724 shares of the stock traded hands, compared to its average volume of 369,378. AnaptysBio has a 1-year low of $15.17 and a 1-year high of $114.47. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.77 and a current ratio of 10.77.
AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.47) by $0.02. analysts forecast that AnaptysBio will post -1.72 earnings per share for the current fiscal year.
A number of hedge funds have recently bought and sold shares of ANAB. TIAA CREF Investment Management LLC bought a new stake in AnaptysBio in the first quarter valued at $227,000. Geode Capital Management LLC bought a new stake in AnaptysBio in the first quarter valued at $1,522,000. Bank of America Corp DE bought a new stake in shares of AnaptysBio during the first quarter valued at about $123,000. Schwab Charles Investment Management Inc. raised its stake in shares of AnaptysBio by 94.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 19,402 shares of the biotechnology company’s stock valued at $465,000 after purchasing an additional 9,414 shares in the last quarter. Finally, Alps Advisors Inc. bought a new stake in shares of AnaptysBio during the second quarter valued at about $436,000. Institutional investors own 75.48% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Royal Bank of Canada Boosts AnaptysBio (ANAB) Price Target to $108.00” was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.thelincolnianonline.com/2018/01/14/anaptysbio-anab-pt-raised-to-108-00-at-royal-bank-of-canada-updated-updated-updated.html.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.